Lerebours F, Pulido M, Fourme E, Debled M, et al. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials. Br J Cancer 2020 Jan 31. pii: 10.1038/s41416-020-0733.
PMID: 32001832